Privacy settings

We use technical cookies, that are necessary for the management of the website, statistical cookies and marketing cookies (including third parties cookies) for displaying individual offers and ads. For more information read our Privacy Policy. Statistical cookies and marketing cookies (inclusive of third parties cookies) are used only with your consent. By clicking “Select all and agree” you consent to our use of statistical and/or marketing cookies (inclusive of third parties cookies).

To customize your privacy settings, tick your preferences in the checkboxes and click “Apply selection”. You can always change the privacy settings and deactivate cookies by following the instructions in the Privacy Policy.

Show preferences Select all and accept
IMA is loading
Post published on 10/04/2020

IMA Active and GSK partners in excellence

GSK Parma site winning the Social Impact category for ISPE 2020 Facility Of the Year Awards.

GSK and ViiV Healthcare were awarded with the ISPE 2020 Facility of the Year Awards for constructing and commissioning a dedicated facility in 15 months to bring to market a new medicine for people living with HIV and ensure continuity of supply of fostemsavir.

The limited product knowledge, as it was acquired form a third party who stopped clinical development, brought unusual challenges. The team collaborated closely with colleagues across all developmental functions and regulatory authorities to understand the impact of the drug on facility design and operation.

To deliver the project, the team used the novel delivery approach of “Integrated Project Delivery” (IPD) never used before in Italy. They paid attention to creating a “can do” attitude and culture whilst implementing accelerated delivery tools such as building information modelling and 3D visualization from design inception to handover enhance collaboration. This pre-construction project visualization improved coordination of scheduling and sequencing throughout the project and was contributory to the excellent safety performance of zero reportable incidents.

For the third time GSK chose IMA Active as main supplier for containment solutions and solid dose processing machines. Once again IMA Active has confirmed its competence and experience. The plant is equipped with IMA state-of-the-art machines to ensure the best and most consistent product quality. Besides the supply of an integrated equipment specifically designed for fostemsavir manufacturing in containment with dedicated control systems, IMA Active experts shared their knowledge to deliver the project and provide assistance for process start-up and optimization. 

As a result of this work, ViiV Healthcare continued the clinical trials and has been able to complete regulatory submissions to the FDA and CHMP. The company is expecting approval of fostemsavir in the US and Europe in 2020.

For further information visit the ISPE website.

Get in touch

Get more info on IMA Active solutions.

Other News

keyboard_arrow_left keyboard_arrow_right